Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

Cancer Cell

Volumn 6, Issue 5, 2004, Pages 507-516

  Oliner, Jonathan ^a   Min, Hosung ^a   Leal, Juan ^a   Yu, Dongyin ^a   Rao, Shashirekha ^a   You, Edward ^a   Tang, Xiu ^a   Kim, Haejin ^a   Meyer, Susanne ^a   Han, Seog Joon ^a   Hawkins, Nessa ^a   Rosenfeld, Robert ^a   Davy, Elyse ^a   Graham, Kevin ^a   Jacobsen, Frederick ^a   Stevenson, Shirley ^a   Ho, Joanne ^a   Chen, Qing ^a   Hartmann, Thomas ^a   Michaels, Mark ^a   Kelley, Michael ^a   Li, Luke ^a   Sitney, Karen ^a   Martin, Frank ^a   Sun, Ji Rong ^a   Zhang, Nancy ^a   Lu, John ^a   Estrada, Juan ^a   Kumar, Rakesh ^a   Coxon, Angela ^a   Kaufman, Stephen ^a   Pretorius, James ^a   Scully, Sheila ^a   Cattley, Russ ^a   Payton, Marc ^a   Coats, Steve ^a   Nguyen, Linh ^a   Desilva, Binodh ^a   Ndifor, Anthony ^a   Hayward, Isaac ^a   Radinsky, Robert ^a   Boone, Tom ^a   Kendall, Richard ^a   more..

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH;

ANIMALIA;

EID: 7944220649     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.09.030     Document Type: Article

References (50)

1. Ahmad S.A., Liu W.B., Jung Y.D., Fan F., Wilson M., Reinmuth N., Shaheen R.M., Bucana C.D., Ellis L.M. The effects of angiopoietin-1 and-2 on tumor growth and angiogenesis in human colon cancer. Cancer Res. 61:2001;1255-1259
2. Anonymous Bevacizumab. Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF. Drugs R D. 3:2002;28-30
3. Bunone G., Vigneri P., Mariani L., Buto S., Collini P., Pilotti S., Pierotti M.A., Bongarzone I. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am. J. Pathol. 155:1999;1967-1976
4. Coxon A., Bolon B., Estrada J., Kaufman S., Scully S., Rattan A., Duryea D., Hu Y.L., Rex K., Pacheco E., et al. Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis Rheum. 46:2002;2604-2612
5. Das A., Fanslow W., Cerretti D., Warren E., Talarico N., McGuire P. Angiopoietin/Tek interactions regulate MMP-9 expression and retinal neovascularization. Lab. Invest. 83:2003;1637-1645
6. Davis S., Aldrich T.H., Jones P.F., Acheson A., Compton D.L., Jain V., Ryan T.E., Bruno J., Radziejewski C., Maisonpierre P.C., Yancopoulos G.D. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 87:1996;1161-1169
7. DeVore, R., Fehrenbacher, L., Herbst, R., Langer, C., Kelly, K., Gaudreault, J., Holmgren, E., Novotny, W., and Kabbinavar, F. (2000). A randomized phase II trial comparing Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. ASCO Abstract 1896.
8. Dumont D.J., Gradwohl G., Fong G.H., Puri M.C., Gertsenstein M., Auerbach A., Breitman M.L. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev. 8:1994;1897-1909
9. Etoh T., Inoue H., Tanaka S., Barnard G.F., Kitano S., Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma. possible in vivo regulation via induction of proteases Cancer Res. 61:2001;2145-2153
10. Fearon U., Griosios K., Fraser A., Reece R., Emery P., Jones P.F., Veale D.J. Angiopoietins, growth factors, and vascular morphology in early arthritis. J. Rheumatol. 30:2003;260-268
11. Folkman J. Antiangiogenic gene therapy. Proc. Natl. Acad. Sci. USA. 95:1998;9064-9066
12. Gale N.W., Yancopoulos G.D. Growth factors acting via endothelial cell-specific receptor tyrosine kinases. VEGFs, angiopoietins, and ephrins in vascular development Genes Dev. 13:1999;1055-1066
13. Gale N.W., Thurston G., Hackett S.F., Renard R., Wang Q., McClain J., Martin C., Witte C., Witte M.H., Jackson D., et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev. Cell. 3:2002;411-423
14. Gerber H.P., Vu T.H., Ryan A.M., Kowalski J., Werb Z., Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 5:1999;623-628
15. Hackett S.F., Wiegand S., Yancopoulos G., Campochiaro P.A. Angiopoietin-2 plays an important role in retinal angiogenesis. J. Cell. Physiol. 192:2002;182-187
16. Hanahan D. Signaling vascular morphogenesis and maintenance. Science. 277:1997;48-50
17. Hangai M., Murata T., Miyawaki N., Spee C., Lim J.I., He S.K., Hinton D.R., Ryan S.J. Angiopoietin-1 upregulation by vascular endothelial growth factor in human retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 42:2001;1617-1625. a
18. Hangai M., Yuen Sung M., Kitaya N., Chan C.K., Wu D.Y., Peters K.G., Ryan S.J., Hinton D.R. Systemically expressed soluble Tie2 inhibits intraocular neovascularization. Hum. Gene Ther. 12:2001;1311-1321. b
19. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., Yancopoulos G.D., Wiegand S.J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 284:1999;1994-1998
20. Hurwitz, H., Fehrenbacher, L., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Griffing, S., Novotny, W., Holmgren, E., and Kabbinavar, F. (2003). Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. ASCO Abstract 3646.
21. Iwama A., Hamaguchi I., Hashiyama M., Murayama Y., Yasunaga K., Suda T. Molecular cloning and characterization of mouse TIE and TEK receptor tyrosine kinase genes and their expression in hematopoietic stem cells. Biochem. Biophys. Res. Commun. 195:1993;301-309
22. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., Meropol N.J., Novotny W.F., Lieberman G., Griffing S., Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21:2003;60-65
23. Kim I., Kim J.H., Moon S.O., Kwak H.J., Kim N.G., Koh G.Y. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Oncogene. 19:2000;4549-4552
24. Kuroda K., Sapadin A., Shoji T., Fleischmajer R., Lebwohl M. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J. Invest. Dermatol. 116:2001;713-720
25. Lin P., Polverini P., Dewhirst M., Shan S., Rao P.S., Peters K. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J. Clin. Invest. 100:1997;2072-2078
26. Lin P., Buxton J.A., Acheson A., Radziejewski C., Maisonpierre P.C., Yancopoulos G.D., Channon K.M., Hale L.P., Dewhirst M.W., George S.E., Peters K.G. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc. Natl. Acad. Sci. USA. 95:1998;8829-8834
27. Lobov I.B., Brooks P.C., Lang R.A. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc. Natl. Acad. Sci. USA. 99:2002;11205-11210
28. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S., Radziejewski C., Compton D., McClain J., Aldrich T.H., Papadopoulos N., et al. Angiopoietin-2, a natural antagonist for tie2 that disrupts in vivo angiogenesis. Science. 277:1997;55-60
29. Miller, K.D., Rugo, H.S., Cobleigh, M.A., Marcom, P.K., Chap, L.I., Holmes, F.A., Fehrenbacher, L., Overmoyer, B.A., Reimann, J.D., Vassel, A.V., and Langmuir, V.K. (2002). Phase III trial of capecitabine (Xeloda(R)) plus bevacizumab (AvastinTM) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Paper presented at: 25th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 11-14, 2002.
30. Mochizuki Y., Nakamura T., Kanetake H., Kanda S. Angiopoietin 2 stimulates migration and tube-like structure formation of murine brain capillary endothelial cells through c-Fes and c-Fyn. J. Cell Sci. 115:2002;175-183
31. Mustonen T., Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J. Cell Biol. 129:1995;895-898
32. Otani A., Takagi H., Oh H., Koyama S., Matsumura M., Honda Y. Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. 40:1999;1912-1920
33. Qian, X.-D., George, J.S., Moskey, M.D., Nelson, C.M., Smith, P.A., Bousquet, P.F., Seshadri, T., Mazdiyasni, H., Arnold, L.D., and Barlozzari, T. (2002). Inhibition of angiogenesis by BSF 466895 (A-422885.66), a potent and selective low molecular weight Tie-2 kinase inhibitor. Paper presented at: 93rd Annual Meeting of the American Association for Cancer Res., San Francisco, CA, April 6-10, 2002.
34. Raymond E., Faivre S., Vera K., Delbaldo C., Robert C., Brega N., Achour A., Massimini G., Schigalla P., Armand J.P. First results of a phase I and pharmacokinetic study of SU011248, a novel oral anti-angiogenic agent, in patients with advanced solid tumours. Eur. J. Cancer. 38:2002;17
35. Rothenberg M.L., Carbone D.P., Johnson D.H. Opinion. improving the evaluation of new cancer treatments: challenges and opportunities Nat. Rev. Cancer. 3:2003;303-309
36. Sato T.N., Tozawa Y., Deutsch U., Wolburg-Buchholz K., Fujiwara Y., Gendron-Maguire M., Gridley T., Wolburg H., Risau W., Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 376:1995;70-74
37. Shahrara S., Volin M.V., Connors M.A., Haines G.K., Koch A.E. Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue. Arthritis Res. 4:2002;201-208
38. Siemeister G., Schirner M., Weindel K., Reusch P., Menrad A., Marme D., Martiny-Baron G. Two independent mechanisms essential for tumor angiogenesis. Inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway Cancer Res. 59:1999;3185-3191
39. Stratmann A., Risau W., Plate K.H. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am. J. Pathol. 153:1998;1459-1466
40. Suri C., Jones P.F., Patan S., Bartunkova S., Maisonpierre P.C., Davis S., Sato T.N., Yancopoulos G.D. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 87:1996;1171-1180
41. Tanaka S., Mori M., Sakamoto Y., Makuuchi M., Sugimachi K., Wands J.R. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J. Clin. Invest. 103:1999;341-345
42. Teichert-Kuliszewska K., Maisonpierre P.C., Jones N., Campbell A.I., Master Z., Bendeck M.P., Alitalo K., Dumont D.J., Yancopoulos G.D., Stewart D.J. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc. Res. 49:2001;659-670
43. Visconti R.P., Richardson C.D., Sato T.N. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc. Natl. Acad. Sci. USA. 99:2002;8219-8224
44. White R.R., Shan S., Rusconi C.P., Shetty G., Dewhirst M.W., Kontos C.D., Sullenger B.A. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc. Natl. Acad. Sci. USA. 100:2003;5028-5033
45. Yang J.C., Haworth L., Steinberg S.M., Rosenberg S.A., Novotny W. A randomized double-blind placebo-controlled trial of bevacizumab anti-VEGF antibody demonstrating a prolongation time to progression in patients with metastatic renal cancer. Proc. Am. Soc. Clin. Oncol. 21:2002;15
46. Yoshida Y., Oshika Y., Fukushima Y., Tokunaga T., Hatanaka H., Kijima H., Yamazaki H., Ueyama Y., Tamaoki N., Miura S., Nakamura M. Expression of angiostatic factors in colorectal cancer. Int. J. Oncol. 15:1999;1221-1225
47. Yu Q., Stamenkovic I. Angiopoietin-2 is implicated in the regulation of tumor angiogenesis. Am. J. Pathol. 158:2001;563-570
48. Yuan K., Jin Y.T., Lin M.T. Expression of Tie-2, angiopoietin-1, angiopoietin-2, ephrinB2 and EphB4 in pyogenic granuloma of human gingiva implicates their roles in inflammatory angiogenesis. J. Periodontal Res. 35:2000;165-171
49. Zagzag D., Hooper A., Friedlander D.R., Chan W., Holash J., Wiegand S.J., Yancopoulos G.D., Grumet M. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp. Neurol. 159:1999;391-400
50. Zangari M., Elias A., Stopeck A., Morimoto A., Tan N., Lancet J., Cooper M., Hannah A., Garcia-Manero G., Faderl S., et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin. Cancer Res. 10:2004;88-95